Session Four of #INOCA2025 looks at how we can build better services and diagnostics for #ANOCA patients.
Talks include:
- Patient Stories
- Setting Up a Service โ Dr. Mark Mariathas, Dr. Tusha Kotecha
- Non-Invasive Diagnostics: CMR โ Prof. Amedeo Chiribiri
- PET, Echo Doppler, and ETT โ Prof. Eva Prescott
Real-world strategies for expanding access to #CMD care.
millbrook-events.co.uk/INOCAโฆ#INOCA2025#CMR#ServiceDesign#CardiologyInnovation
BANCC are pleased to invite you to register for our upcoming webinar 'Angina/Ischemia with Non-Obstructive Coronary Arteries (ANOCA & INOCA) โ how to assess, treatment options and the patient perspective' on Wednesday, 15 October 2025 19:00 - 20:20.
members.bancc.org.uk/events/โฆ
๐2 weeks to go to INOCA 2025!
๐London SE1 7AR
@TheBHF@NIHRresearch
Incredible international faculty
How to sessions
Guideline updates
Informative talks
Debates
Live cases
Lived experience
Innovations in INOCA
โผ๏ธRegister ASAP
millbrook-events.co.uk/eventโฆ
' ANOCA progressed from the initial scepticism of the scientific community regarding its existence to the demonstration of its clinical relevance and the need for a standardized diagnostic algorithm (as recommended in current ESC Guidelines)'
academic.oup.com/eurheartj/aโฆ
Everything you wanted to know about INOCA in 2 days! Well worth registering asap for #INOCA2025, a @TheBHF - @NIHRresearch CV partnership meeting. Stellar international faculty, guideline updates, how to sessions, debates, breaking research, discussion, live cases and more!
Registration is OPEN for #INOCA2025!
๐๏ธ 25โ26 Sept | ๐ London
Join @divaka_perera and @achir76, for two days of cutting-edge insights into Coronary Microvascular Dysfunction.
โ Live cases
โ Patient stories
โ Tech & trials
โ Real-world clinical tools
Register here: millbrook-events.co.uk/INOCAโฆ
Four years in the making, weโre finally here. Congratulations to our colleagues Peter Damman & team for their 1st patient in #iCorMicA! Thank you for the hospitality and cath lab tips. Fantastic team and beautiful campus at Radboud UMC Nijmegen. It was an absolute delight. #INOCA
We are delighted to announce our first educational and Q&A session about Patient and Public Involvement in Research!
โก๏ธHave a question or topic youโd like covered? Let us know and register here by 24th June: forms.office.com/pages/respoโฆ
More info: enquiries@bhfcrc.org
Thank you to everyone who passed on the details of our survey.
CONGRATULATIONS to all who took Survey 1! You are, in part, going to the ESC (European Society of Cardiology) Congress with Sarena La on August 29th in Madrid.
@sarena_lasurveys.adelaide.edu.au/redcโฆ
Please help us to help you.
We have collaborated with Adelaide University to develop a series of patients surveys.
The results will help to identify #ANOCA patients
& co-design future care pathways.
Please share with patients & clinicians
#ANOCA#INOCA#MINOCA
Congratulation to Her Heart Australia on their 10year Anniversary Event in Melbourne. Our Co Founder Cindy McCall was honored to be on a panel sharing her experiences, creating awareness of what heart disease truly looks like.
Bravo @Heartspasms1 finally meets
@RosannaTavella
Happy Nurseโs Week!
Thank you to all the nurses who advocate for patients and watch out for them in vulnerable moments! They are the backbone of our care.
While the umbrella term #ANOCA is useful, it's important to determine whether a person's symptoms are due to microvascular dysfunction, microvessel or coronary artery vasospasms.
1/8
Diltiazem for ANOCA: Whatโs the real story?
Letโs break down the EDIT-CMD trial and what it does (and doesnโt) tell us about treating coronary vasomotor dysfunction with diltiazem.
#CardioTwitter#ANOCA#CMD
The WARRIOR trial was ambitious, but without endotyping, outcomes didnโt change.
Dr. Jay Widmer (@DrArgyle) explains why individualized testing is critical for advancing care in INOCA.
๐ฅ Full breakdown now on YouTube! youtu.be/eequD8jTQhA#Cardiology#ACC2025#CathLab
#WARRIโค๏ธR @ACC2025
2476 โ pts w/ INOCA, intensive medical rx vs usual care:
โ Didnt reduce MACE by 20% at 5y fu
๐จCautious interpretation of results: insufficient adherence, power
โ๏ธ Do NOT d/c statins and ACEi/ARB
โผ๏ธAdditional data are needed in this growing pt population
WARRIOR: Hear From Elizabeth Dineen, DO, FACC, on the WARRIOR trial from #ACC25 which found that intensive medical therapy did ๐ซ significantly impact the rate of serious CV events at 5๏ธโฃ years in women w/ suspected INOCA.
๐ Watch on #ACCAnywhere TV: bit.ly/3FJdX34